The HLCS Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for targeted disruption of the holocarboxylase synthetase (HLCS) gene in a human colorectal adenocarcinoma background. This polyclonal population is derived from the HT29 cell line and provides a versatile loss-of-function model for investigating biotin-dependent metabolic pathways. The gene-edited cells retain the epithelial characteristics of the parental HT29 line while lacking functional HLCS, enabling robust interrogation of biotinylation-dependent processes in colon cancer research.
The HT29 cell line is a widely used human colorectal adenocarcinoma model established from a primary colon tumor, exhibiting epithelial morphology. HT29 cells serve as a relevant in vitro system for colorectal cancer studies, metabolic investigations, and epithelial cell biology due to their well-characterized growth properties and ability to form polarized monolayers. Their adenocarcinoma origin provides a clinically pertinent context for exploring how metabolic perturbations, such as impaired biotin utilization, influence malignant phenotypes.
HLCS encodes an enzyme that catalyzes the ATP-dependent covalent attachment of biotin to apocarboxylases, a modification essential for the activity of acetyl-CoA carboxylase (ACC, encoded by ACACA and ACACB), pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCCA/PCCB), and 3-methylcrotonyl-CoA carboxylase (MCCC1/MCCC2). HLCS function is regulated upstream by biotin availability and by transcription factors SP1 and NF-Y, and it acts downstream of biotin transporters such as SLC5A6. Knockout of HLCS in this polyclonal population ablates biotinylation of these target carboxylases, thereby disrupting key metabolic pathways including gluconeogenesis, fatty acid synthesis, and leucine degradation.
In the context of HT29 colorectal adenocarcinoma cells, loss of HLCS-mediated biotinylation compromises carboxylase-driven metabolic reactions, potentially altering the metabolic repertoire of the cancer cell. Colorectal tumors often exhibit reprogrammed energy metabolism, and HLCS disruption may impact lipogenesis and anaplerotic reactions critical for proliferation and survival. This model thus offers a unique tool to dissect the intersection of biotin metabolism and colon cancer cell biology, and to study how carboxylase deficiencies contribute to metabolic acidosis and related disorders.
This knockout cell population is adapted for diverse experimental applications, including biotin metabolism studies, holocarboxylase synthetase deficiency modeling, and investigation of multiple carboxylase deficiency. Researchers can employ western blotting to detect biotinylated proteins, carboxylase activity assays to assess residual enzyme function, RT-qPCR for transcript analysis, metabolic flux analysis using labeled substrates, and biotin deprivation assays to probe cellular dependency on exogenous biotin. For additional information or support, please contact Ascent Research.
